Maraviroc for HIV: Responses at 48 Weeks
/
RSS Feed
Jacob Lalezari
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
You may also like...
Ovarian Stimulation Does Not Affect Fetal Birth Weight – reporting from 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4 July 2007, Lyon, France 2 Aug, 2007 - Community-Associated MRSA: Public Housing, Jail: Risks? 4 Jan, 2006
- Lifestyle and Heart Disease in Europe: A Growing Problem 2 Sep, 2007
- Tuberculosis: Non-Adherence to Treatment is a Major Obstacle to Therapy Success 9 Aug, 2007
